UK competition watchdog said firm paid drugmakers £50m in return for delaying cheaper generic versions of drug GlaxoSmithKline has been fined £37.6m by Britain’s competition authority for “illegal behaviour” in relation to its antidepressant Seroxat that resulted in higher costs for the NHS.
The Competition & Markets Authority said the pharmaceutical firm had paid generic drugmakers more than £50m between 2001 and 2004 in return for them delaying the launch of cheaper versions of the blockbuster paroxetine drug,branded Seroxat, which sold more than £90m in 2001.
Continue reading...
Source: theguardian.com